Status:
COMPLETED
Safety and Efficacy of Iron Reduction by Phlebotomy
Lead Sponsor:
Andrea Kew
Conditions:
Iron Overload
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Hypothesis: The reduction of total body iron by phlebotomy will be safe and feasible in the post-HSCT setting Iron overload is common after hematopoietic stem cell transplantation. It is associated w...
Detailed Description
Background Hematopoietic stem cell transplantation (HSCT) is increasingly used as a treatment for a variety of malignant and non-malignant conditions. With improvements in conditioning regimens and po...
Eligibility Criteria
Inclusion
- consecutive patients who have undergone autologous or allogeneic HSCT
- who are red-cell transfusion-independent
- at least 60 days post-transplant
- serum ferritin of at least 1000ug/L
- ECOG less than or equal to 2.0
Exclusion
- pregnancy
- breast-feeding
- serious infection
- HIV antibody positive
- renal failure (creatinine \< 30ml/min)
- sever obstructive lung disease
- have a pacemaker, cerebral aneurysm or metal prosthesis
- evidence of disease relapse
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00689182
Start Date
May 1 2007
End Date
December 1 2012
Last Update
January 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada, B3h 2Y9